StreetAlpha.app
Home › Stocks › BCAX

Bicara Therapeutics Inc. (BCAX)

Healthcare
$8.44
▼ −7.46%
LAST CLOSE · NOV 20

Bicara Therapeutics develops ficerafusp alfa, an investigational antibody therapy for solid tumors such as head and neck cancers. It last closed at $8.44 on Nov 20, down 7.46% on the day. The next earnings report for BCAX is expected around Thu, Feb 25, 2027, after the close. For the quarter ended Sep 2026, BCAX reported EPS of -$1.04. Over its last 8 reports the stock moved an average of 6.6% the session after earnings. Over the last 12 months BCAX insiders bought $4.8M of stock on the open market and sold $9.9M, according to SEC Form 4 filings.

AI Auto Pilots
Is BCAX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold BCAX.

Key Stats

Last 12 months
Results
Net income
−$220.3M
EPS (diluted)
−$3.46
−164.3% vs a year ago
Free cash flow
−$162.8M
Valuation
Market cap
$560.3M
66.4M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$82.0M
At Sep 30
Shareholder equity
$409.4M
Shares outstanding
66.4M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: −$52.0M−$52.0MFY2023FY2024: −$68.0M−$68.0MFY2024FY2025: −$137.9M−$137.9MFY2025

From BCAX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · After the close
Reported EPS
-$1.04
Quarter ended Sep 2026
Year ago EPS
-$0.67
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $7.22Dec '24Mar 2025: -$0.68Mar '25Jun 2025: -$0.50Jun '25Sep 2025: -$0.67Sep '25Dec 2025: -$0.68Dec '25Mar 2026: -$0.93Mar '26Jun 2026: -$0.82Jun '26Sep 2026: -$1.04Sep '26Latest -$1.04
Revenue by quarter
Not enough quarters on file yet.
How BCAX moved after its last 8 reports
Average move the session after a report ±6.6%
Nov 9, 2026Time not announced+15.4%
Aug 11, 2026Time not announced−14.3%
May 11, 2026Time not announced+1.5%
Mar 30, 2026Time not announced+3.6%
Feb 26, 2026After the close−0.1%
Nov 10, 2025Time not announced−4.8%
Aug 12, 2025Time not announced+4.8%
May 13, 2025Time not announced−8.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on BCAXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on BCAX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on BCAX

Technical Analysis

BCAX · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 20% below its 20 day and 83% below its 50 day average. It is 145% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the Pivot S1 at $8.20, and the nearest resistance the Pivot at $8.67.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 12.2%/day
Key levels
$30.9952 week high+267.2%
$20.72100 day average+145.5%
$20.65200 day average+144.7%
$15.4350 day average+82.8%
$11.45Swing high (Nov 11)+35.7%
$10.1420 day average+20.1%
$8.91Pivot R1+5.6%
$8.67Pivot+2.7%
$8.44Last close
$8.20Pivot S1−2.8%
$7.8752 week low−6.8%
$7.87Swing low (Nov 2)−6.8%
Indicators
RSI (14)28.24Oversold below 30Oversold
MACD-1.89Above its signal lineBullish
Stochastic30.8Middle of its rangeNeutral
ADX (14)47.2Strong downtrend
Williams %R-84.8Oversold below −80, overbought above −20Oversold
CCI (20)-66.0Oversold below −100, overbought above 100Neutral
Rate of change−2.4%Change over 10 sessionsBearish
ATR (14)$1.03Typical daily range, 12.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BCAX

What happened before

See how BCAX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for BCAXHow many large options trades hit BCAX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

BCAX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲96 buying vs 66 selling
  • ▼Held by funds -0.6 pts
  • ▼Funds holding -3
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding169172−1.7%
In funds' top 1059−44.4%
Held by funds104.5%105.1%−0.6 pts
New / increased25 / 7136 / 68−7.7%
Reduced / sold out39 / 2738 / 11+34.7%
Put/call ratio0.191.00−81.1%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BCAX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

BCAX Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$4.8M1 buy · 1 insider
Sold$9.9M33 sales · 4 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 sold $402K2026-01 sold $106K2026-02 bought $4.8M2026-02 sold $66K2026-03 sold $2.6M2026-04 sold $979K2026-05 sold $742K2026-07 sold $1.9M2026-08 sold $1.2M2026-09 sold $401KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 8Ryan CohlheppPresident, COO & Interim CEOSale plan17,500$22.90$401K
Aug 10Ryan CohlheppPresident and COOSale plan18,750$27.98$525K
Aug 10Claire MazumdarCEOSale plan10,000$27.98$280K
Aug 10Ivan HyepCFOSale plan12,500$27.97$350K
Jul 10Claire MazumdarCEOSale plan10,000$28.42$284K
Jul 9Ryan CohlheppPresident and COOSale plan28,750$28.98$833K
Every insider buy and sale for BCAX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See BCAX insider trades →

From SEC Form 4 filings by BCAX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BCAX is in one of them and how their past BCAX trades turned out.

BCAX in the AI portfolios
Loading…

BCAX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BCAX in an article yet. Here's the latest on the wider market.

BCAX in the news

About Bicara Therapeutics

Bicara Therapeutics is a biopharmaceutical company based in Boston, Massachusetts, that is developing treatments for solid tumors. Its main candidate, ficerafusp alfa, is an investigational antibody that pairs an antibody targeting the EGFR protein on tumor cells with a molecule that blocks TGF-β, a signaling protein that helps tumors resist treatment. The candidate is being tested mainly in head and neck squamous cell carcinoma, and the company does not yet sell a product. Its intended patients are people with solid tumors, starting with head and neck cancers.

Headquarters
Boston, MA